
Arrange your collection
Choose your location, add the test to your care bag and select a time. If you are booking for someone else, assign the test to them in checkout.
Choose collection locationTumour Markers · Individual laboratory test
CA 19-9 may be followed in selected pancreatic or biliary conditions. Bile duct obstruction and other non-cancerous conditions can also raise it.
Clinical authorDr Nirupama SabhapathySpecialist Clinical Pathology
Understanding the test
Also called Pancreatic & GI Marker
A specialist may request a baseline or serial CA 19-9 in the management of selected pancreatic or biliary cancers.
CA 19-9 can assist monitoring in selected pancreatic or biliary cancers when a specialist considers it appropriate.
Bile duct obstruction and inflammation are among the possible non-cancerous causes.
Before your sample
No fasting is generally needed. Mention jaundice, gallstones or a recent bile duct stent or drain before comparing CA 19-9 results.
A clinician takes a small sample of blood from a vein. The laboratory uses serum, the liquid separated from the blood after it clots.
Smart Report
24 hoursLaboratory turnaround
CA 19-9 can rise with obstruction or inflammation and may be low even when disease is present. A trend should be interpreted in the clinical setting in which it was obtained.
From sample to follow-up

Choose your location, add the test to your care bag and select a time. If you are booking for someone else, assign the test to them in checkout.
Choose collection locationLook for CA-19-9 in your report. Use the sample type and collection time when comparing it with an earlier report.
Explore Smart Report
Mention any recent change in jaundice or bile duct treatment when comparing CA 19-9 with earlier results.
Health packages
Compare the other tests in each package before choosing.
Patient questions
Impaired bile flow can raise the marker independently of cancer. The clinician may interpret it alongside bilirubin, imaging and changes over time.
No. Pancreatic cancer is the cancer it is most strongly associated with, but cholangiocarcinoma and other cancers of the bile ducts also raise it, as can gastric, colorectal and some ovarian and lung cancers. A raised value therefore does not point to one organ on its own, and imaging is what locates the source.
Values from different assays are not directly comparable, so switching laboratories can create an apparent change that is really a difference in method. Because the trend is what your doctor reads, give each sample through the same laboratory where possible and bring your previous results, so each new value can be set against the ones before it.
KEEP EXPLORING
Open a package to see exactly which tests it includes.

A defined selection of tumour markers, with a blood count and stool occult blood, for clinician-directed assessment. These results cannot confirm or rule out cancer on their own.

A defined tumour-marker selection including PSA, with a blood count and stool occult blood, for clinician-directed assessment. Results cannot confirm or rule out cancer alone.

Blood count, liver, kidney, cholesterol, blood sugar and urine tests: the essentials in one visit.

A complete blood count with liver enzymes, cholesterol, kidney markers and fasting blood sugar from one blood sample.
Choosing for a particular need?
We can help you read the options.
Your next step
Written by Dr Nirupama Sabhapathy, Specialist Clinical Pathology. Medically reviewed by Dr Joyce Jose, Specialist Clinical Pathology, on .
Catalogue information and AED price checked on 2 November 2026. Clinical suitability, preparation, collection arrangements and turnaround are confirmed for your selected test.